Obinutuzumab treatment for membranous nephropathy: effectiveness and safety concerns during the COVID-19 pandemic
Lists
Only you see this
Abstract
Obinutuzumab was an effective treatment option for patients with membranous nephropathy. On the other hand, it was associated with a higher incidence of severe pneumonia following COVID-19 infection compared to other immunosuppressive regimens.
BibTeX
@inproceedings{xu2024obinutuzumab,
author = {Mingyue Xu and Ruiying Chen and Yifeng Wang and Xiaoyun Huang and Hanzhen Zhang and Wenqian Zhao and Min Zhang and Yunyu Xu and Shaojun Liu and Chuan‐Ming Hao and Qionghong Xie},
title = {{Obinutuzumab treatment for membranous nephropathy: effectiveness and safety concerns during the COVID-19 pandemic}},
booktitle = {Clinical},
year = {2024},
doi = {10.1093/ckj/sfae299},
}Loading related content...